Zemlan, Ph.D., President and Chairman of the Board, has
over 20 years of experience in clinical research for Fortune 500 drug companies including Novartis, Pfizer and Eli Lilly.
Frank holds several biotech patents and has direct experience in drug licensing and intellectual property management. He has
started two successful biotech companies, Mind Probes - a diagnostic company that licensed its platform technology to Biosite
(Nasdaq: BSTE) and Phase 2 Discovery that out-licensed its proprietary Phase 3-ready insomnia drug. Frank received his
graduate training at the University of Pennsylvania School of Medicine and has served on the faculty of Princeton University,
Rockefeller University in New York City and the University of Cincinnati College of Medicine where he attained the rank of
tenured University Professor. Frank serves on several national grant review committees including the Center for Scientific
Review at the National Institutes of Health and is a reviewer for many journals in the fields of psychiatry and neuroscience.
He is the author of over 200 scientific publications and book chapters.
Prasad Gabbita, Ph.D., Chief Executive Officer, has lead the preclinical drug discovery, development and biomarker
assay programs at P2D Bioscience and its predecessor companies for the past ten years. He brings 15 years of research
experience and knowledge in neuroscience, toxicology, synthetic organic chemistry and drug formulation. Prasad received
his doctoral and post-doctoral training at the University of Kentucky College of Medicine and Sanders Brown Center on Aging
in Lexington. He has been the recipient of nearly $ 2 MM in research funding for drug and diagnostic development from
several agencies including the Michael J. Fox Foundation, the Alzheimer’s Drug Discovery Foundation and the National
Institutes of Health. Prasad has authored about 20 peer-reviewed scientific publications and book chapters.